ATE353964T1 - Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen - Google Patents
Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungenInfo
- Publication number
- ATE353964T1 ATE353964T1 AT98918453T AT98918453T ATE353964T1 AT E353964 T1 ATE353964 T1 AT E353964T1 AT 98918453 T AT98918453 T AT 98918453T AT 98918453 T AT98918453 T AT 98918453T AT E353964 T1 ATE353964 T1 AT E353964T1
- Authority
- AT
- Austria
- Prior art keywords
- crsp
- proteins
- nucleic acid
- encod
- cystein
- Prior art date
Links
- 101100385295 Arabidopsis thaliana CRSP gene Proteins 0.000 title abstract 5
- 101100007768 Sus scrofa CRSP1 gene Proteins 0.000 title abstract 5
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 101150065762 CRSP gene Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84370497A | 1997-04-16 | 1997-04-16 | |
| US84289897A | 1997-04-17 | 1997-04-17 | |
| US7158998P | 1998-01-15 | 1998-01-15 | |
| US980298A | 1998-01-20 | 1998-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE353964T1 true ATE353964T1 (de) | 2007-03-15 |
Family
ID=27485904
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06021943T ATE505543T1 (de) | 1997-04-16 | 1998-04-16 | Zusammensetzung, umfassend einen antikörper, der selektiv an ein cysteinreiches sekretiertes protein (crsp) bindet |
| AT98918453T ATE353964T1 (de) | 1997-04-16 | 1998-04-16 | Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06021943T ATE505543T1 (de) | 1997-04-16 | 1998-04-16 | Zusammensetzung, umfassend einen antikörper, der selektiv an ein cysteinreiches sekretiertes protein (crsp) bindet |
Country Status (11)
| Country | Link |
|---|---|
| EP (3) | EP0975755B2 (de) |
| JP (4) | JP2001524824A (de) |
| AT (2) | ATE505543T1 (de) |
| AU (2) | AU7137398A (de) |
| CA (1) | CA2288430C (de) |
| CY (1) | CY1107629T1 (de) |
| DE (2) | DE69837085T3 (de) |
| DK (1) | DK0975755T3 (de) |
| ES (1) | ES2285768T5 (de) |
| PT (1) | PT975755E (de) |
| WO (1) | WO1998046755A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7057017B2 (en) | 1997-04-16 | 2006-06-06 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| ES2359401T3 (es) * | 1997-08-01 | 2011-05-23 | Merck Serono Biodevelopment | ESTs 5¿PARA PROTEÍNAS SECRETADAS, EXPRESADAS EN DIVERSOS TEJIDOS. |
| DE19747418C1 (de) | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| US7446181B2 (en) | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
| US6344541B1 (en) * | 1998-09-25 | 2002-02-05 | Amgen Inc. | DKR polypeptides |
| AU6188599A (en) * | 1998-10-26 | 2000-05-15 | Novozymes A/S | Constructing and screening a dna library of interest in filamentous fungal cells |
| AU3510200A (en) * | 1999-03-05 | 2000-09-21 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| US7115665B1 (en) | 2000-11-16 | 2006-10-03 | Onocozyme Pharma, Inc. | Inhibitors of endo-exonuclease activity for treating cancer |
| EP1234877B1 (de) * | 1999-11-19 | 2010-06-02 | Kumon, Hiromi | Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie |
| JP2003528300A (ja) * | 2000-02-24 | 2003-09-24 | オックスフォード グリコサイエンセス(ユーケー) リミテッド | 神経精神及び神経障害におけるdpi−6、推定上の治療ターゲットおよびバイオマーカー |
| US7927597B2 (en) | 2001-04-10 | 2011-04-19 | Agensys, Inc. | Methods to inhibit cell growth |
| EP2280030A3 (de) | 2001-04-10 | 2011-06-15 | Agensys, Inc. | Nukleinsäuren und zugehörige Proteine für die Behandlung und den Nachweis von Krebs |
| US7682607B2 (en) | 2001-05-01 | 2010-03-23 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| US20040038860A1 (en) | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
| US7473770B2 (en) | 2003-11-17 | 2009-01-06 | Merck & Co., Inc. | Cynomolgus monkey dickkopf-4, nucleotides encoding same, and uses thereof |
| WO2005049640A2 (en) | 2003-11-17 | 2005-06-02 | Merck & Co., Inc. | Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof |
| US7867699B2 (en) | 2004-03-23 | 2011-01-11 | Wyeth | Method of synthesizing and purifying Dkk proteins and Dkk proteins obtained thereby |
| CA2574881C (en) | 2004-08-04 | 2013-01-08 | Amgen Inc. | Antibodies to dkk-1 |
| AR060017A1 (es) | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| US7465585B1 (en) | 2006-04-10 | 2008-12-16 | The Burnham Institute | Compositions and methods for inhibiting cell migration |
| AR075989A1 (es) | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (de) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimäre Rezeptoren durch Verbindung und Expression von DNS |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| ATE141646T1 (de) | 1986-04-09 | 1996-09-15 | Genzyme Corp | Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0768377A1 (de) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
| JPH04501510A (ja) | 1989-07-25 | 1992-03-19 | セル ジェネシス,インコーポレイティド | 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同性組換え |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
| MC2311A1 (fr) | 1990-07-10 | 1993-09-27 | Smithkline Beecham Corp | Oxamides |
| WO1992009688A1 (en) | 1990-11-21 | 1992-06-11 | Massachusetts Institute Of Technology | MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| DE69233769D1 (de) | 1991-03-01 | 2009-09-24 | Dyax Corp | Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon |
| AU662148B2 (en) | 1991-04-10 | 1995-08-24 | Scripps Research Institute, The | Heterodimeric receptor libraries using phagemids |
| EP0606217B2 (de) | 1991-06-27 | 2008-12-03 | Bristol-Myers Squibb Company | CTL4A Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendungen |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| CA2148252C (en) | 1992-10-30 | 2007-06-12 | Roger Brent | Interaction trap system for isolating novel proteins |
| CA2153387A1 (en) | 1993-01-07 | 1994-07-21 | Hubert Koester | Dna sequencing by mass spectrometry |
| JP2879303B2 (ja) * | 1993-01-14 | 1999-04-05 | 佑 本庶 | cDNAライブラリーの作製方法、および新規なポリペプチドとそれをコードするDNA |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| EP0954575A2 (de) * | 1996-12-20 | 1999-11-10 | Human Genome Sciences, Inc. | Fuer das zerebellum und embryo spezifisches protein |
| DE19747418C1 (de) * | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
-
1998
- 1998-04-16 AU AU71373/98A patent/AU7137398A/en not_active Abandoned
- 1998-04-16 DE DE69837085T patent/DE69837085T3/de not_active Expired - Lifetime
- 1998-04-16 EP EP98918453A patent/EP0975755B2/de not_active Expired - Lifetime
- 1998-04-16 EP EP10010403A patent/EP2298899A3/de not_active Withdrawn
- 1998-04-16 ES ES98918453T patent/ES2285768T5/es not_active Expired - Lifetime
- 1998-04-16 JP JP54436198A patent/JP2001524824A/ja active Pending
- 1998-04-16 EP EP06021943A patent/EP1852507B1/de not_active Expired - Lifetime
- 1998-04-16 AT AT06021943T patent/ATE505543T1/de not_active IP Right Cessation
- 1998-04-16 CA CA2288430A patent/CA2288430C/en not_active Expired - Lifetime
- 1998-04-16 PT PT98918453T patent/PT975755E/pt unknown
- 1998-04-16 WO PCT/US1998/007894 patent/WO1998046755A1/en not_active Ceased
- 1998-04-16 AT AT98918453T patent/ATE353964T1/de active
- 1998-04-16 DK DK98918453T patent/DK0975755T3/da active
- 1998-04-16 DE DE69842225T patent/DE69842225D1/de not_active Expired - Lifetime
-
2005
- 2005-12-22 JP JP2005370262A patent/JP2006166917A/ja active Pending
-
2007
- 2007-05-14 CY CY20071100650T patent/CY1107629T1/el unknown
-
2009
- 2009-08-17 JP JP2009188614A patent/JP2010011853A/ja active Pending
- 2009-10-22 AU AU2009227915A patent/AU2009227915A1/en not_active Abandoned
-
2010
- 2010-05-13 JP JP2010111163A patent/JP2010227110A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69837085D1 (de) | 2007-03-29 |
| PT975755E (pt) | 2007-06-26 |
| ES2285768T3 (es) | 2007-11-16 |
| EP0975755A1 (de) | 2000-02-02 |
| ES2285768T5 (es) | 2011-12-22 |
| DK0975755T3 (da) | 2007-06-11 |
| ATE505543T1 (de) | 2011-04-15 |
| CY1107629T1 (el) | 2013-06-19 |
| EP0975755B9 (de) | 2007-08-29 |
| EP0975755B2 (de) | 2011-08-03 |
| AU2009227915A1 (en) | 2009-11-12 |
| DE69837085T2 (de) | 2007-11-22 |
| EP2298899A2 (de) | 2011-03-23 |
| DE69842225D1 (de) | 2011-05-26 |
| EP1852507B1 (de) | 2011-04-13 |
| JP2010011853A (ja) | 2010-01-21 |
| EP1852507A1 (de) | 2007-11-07 |
| DE69837085T3 (de) | 2012-01-12 |
| JP2006166917A (ja) | 2006-06-29 |
| CA2288430A1 (en) | 1998-10-22 |
| CA2288430C (en) | 2013-04-09 |
| AU7137398A (en) | 1998-11-11 |
| WO1998046755A1 (en) | 1998-10-22 |
| EP0975755B1 (de) | 2007-02-14 |
| JP2001524824A (ja) | 2001-12-04 |
| EP2298899A3 (de) | 2011-08-24 |
| JP2010227110A (ja) | 2010-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107629T1 (el) | Πρωτεïνη crsp (πλουσιες σε κυστεïνη εκκρινομενες πρωτεïνες) μορια νουκλεϊνικου οξεως που τις κωδικοποιουν και χρησεις τους | |
| FR19C1020I1 (fr) | Nouvelles molecules b7-4 et leurs utilisations | |
| ATE366814T1 (de) | Gl50 moleküle, sowie verwendungen derselben | |
| WO1999066025A3 (en) | Mtbx protein and nucleic acid molecules and uses therefor | |
| ATE356137T1 (de) | Neue moleküle aus der familie der tango-77- ähnlichen proteine und ihre verewendungen. | |
| WO2002070652A3 (en) | Novel molecules of the card-related protein family and uses thereof | |
| ATE419358T1 (de) | Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins | |
| WO2000052047A3 (en) | Human dickkopf-related protein and nucleic acid molecules and uses therefor | |
| WO2002044354A3 (en) | Molecules of the card-related protein family and uses thereof | |
| WO2001000826A3 (en) | Novel molecules of the card-related protein family and uses thereof | |
| WO2000019988A8 (en) | NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF | |
| DE60031418D1 (de) | 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen | |
| WO2000012544A3 (en) | Novel irap-bp polypeptide and nucleic acid molecules and uses therefor | |
| WO2001018216A3 (en) | 26176, a novel calpain protease and uses thereof | |
| WO2000008045A3 (en) | Novel molecules of the tango-93-related protein family and uses thereof | |
| WO1999054437A3 (en) | Novel molecules of the t125-related protein family and uses thereof | |
| WO2001030971A3 (en) | Novel molecules and the card-related protein family and uses thereof | |
| WO2001077151A3 (en) | Fdrg proteins and nucleic acid molecules and uses therefor | |
| WO2002085939A8 (en) | Novel molecules of the card-related protein family and uses thereof | |
| WO2000018890A3 (en) | Protein phosphatase molecules and uses therefor | |
| WO2001073074A3 (en) | 18806, a novel trypsin serine protease-like molecule and uses thereof | |
| WO1999062943A3 (en) | Novel molecules of the aip-related protein family and uses thereof | |
| WO2001083523A3 (en) | Stmst protein and nucleic acid molecules and uses therefor | |
| WO1999067387A3 (en) | Novel mp-7 protein and nucleic acid molecules and uses therefor | |
| WO2001040468A3 (en) | Molecules of the card-related protein family and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0975755 Country of ref document: EP |